Oxcarbazepine (Epilepsy)

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12542
R47232		 Dreier (Oxcarbazepine), 2021 Small for gestational age (birth weight below the 10th percentile for GA, sex and country) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.37 [1.13;1.65] -/1,459   -/- - 1,459
ref
S8084
R24700		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 7.80 [0.23;262.83] C
excluded (control group) 		1/4   0/7 1 4
ref
S8075
R24640		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 25.80 [0.81;819.45] C 1/4   0/22 1 4
ref
S7808
R23129		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Small for gestational age (weight) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.00 [0.58;1.74] C 14/143   167,376/1,710,441 167,390 143
ref
S8146
R25048		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.99 [0.59;6.72]
excluded (control group) 		-/-   -/- - -
ref
S8142
R25020		 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.61 [0.79;3.28] -/-   41,653/1,440,631 41,644 -
ref
S5927
R15102		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 Small for gestational age (weight) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 3.02 [0.69;13.17] C
excluded (control group) 		18/527   2/173 20 527
ref
S5910
R14900		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 Small for gestational age (weight) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.64 [1.02;2.64]
excluded (control group) 		18/527   14,079/719,509 14,097 527
ref
S5918
R14996		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Small for gestational age (weight) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.52 [0.91;2.53] 18/527   42/1,793 60 527
ref
Total 5 studies 1.37 [1.12;1.67] 209,095 2,133
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Dreier (Oxcarbazepine), 2021Dreier, 2021 1 1.37[1.13; 1.65]-1,45966%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 2 25.80[0.81; 819.45]140%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 3 1.00[0.58; 1.74]167,39014312%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Cohen, 2019 4 1.61[0.79; 3.28]41,644-7%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 5 1.52[0.91; 2.53]6052714%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 8% 1.37[1.12; 1.67]209,0952,1330.5100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine) (Controls unexposed, NOS; 4: Oxcarbazepine) (Controls unexposed NOS; 5: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.37[1.12; 1.67]209,0952,1338%NADreier (Oxcarbazepine), 2021 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 5 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.20[0.76; 1.89]209,0341437%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 unexposed, sickunexposed, sick 1.45[1.04; 2.03]611,99030%NADreier (Oxcarbazepine), 2021 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 3 Tags Adjustment   - No  - No 3.19[0.15; 67.31]167,39114770%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 2   - Yes  - Yes 1.40[1.18; 1.66]41,7041,9860%NADreier (Oxcarbazepine), 2021 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 3 All studiesAll studies 1.37[1.12; 1.67]209,0952,1338%NADreier (Oxcarbazepine), 2021 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 50.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.14.52.1170.000Dreier (Oxcarbazepine), 2021Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Artama (Oxcarbazepine) (Controls unexposed, sick), 2013

Asymetry test p-value = 0.3930 (by Egger's regression)

slope=0.2007 (0.1428); intercept=0.7585 (0.7621); t=0.9952; p=0.3930

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 5927, 5910, 8146, 8084

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.38[1.00; 1.91]223,1316700%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 3 unexposed, sick controlsunexposed, sick controls 1.45[1.04; 2.03]611,99030%NADreier (Oxcarbazepine), 2021 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.55[1.03; 6.32]215310%NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 30.510.01.0